Articles written specifically for the GLP or articles that are reposted from other sources (sometimes in modified form) by agreement or with permission list the source as Genetic Literacy Project. Excerpted articles posted in our Daily Digests are identified as excerpts of posts culled from the web. Each Daily Digest post lists the original media outlet as the source next to the name of the author. Excerpts are posted under guidelines for Fair Use and Creative Commons for educational nonprofits (501c3). The GLP’s Fair use policy for posting excerpts and using images is explained here.
Here’s the skinny on the CRISPR patent saga between the Broad Institute and the CVC group

Here’s the skinny on the CRISPR patent saga between the Broad Institute and the CVC group

Kevin Noonan | Endpoints News | 
CRISPR was first reported by Jennifer Doudna and Emmanuelle Charpentier in 2012, as an outgrowth of their work on bacterial ...
‘Exceptionally potent yet easily scalable’: Synthetic biology-based COVID vaccine could pull ahead of current frontrunners

‘Exceptionally potent yet easily scalable’: Synthetic biology-based COVID vaccine could pull ahead of current frontrunners

Jason Mast | Endpoints News | 
Years ago, researchers learned that, when made with biotechnology, some viral proteins could spontaneously assemble themselves into “virus-like particles,” or ...
In a politically divided America, here's how the biotechnology sector sees its future

In a politically divided America, here’s how the biotechnology sector sees its future

Jason Mast | Endpoints News | 
[W]hat does Joe Biden’s presidency mean for biopharma? Part of that question will rest on whether Democrats can pull of ...
china

Chinese biopharma firms ‘well ahead’ in race to use CRISPR in humans

John Carroll | Endpoints News | 
Contrary to what you might believe, biopharma companies in the US are not the leaders in clinical trials using gene ...
glp menu logo outlined

Newsletter Subscription

* indicates required
Email Lists